BACIL PHARMA : WOS SIGNS RS 35 CR R&D AGREEMENT

• Wholly owned subsidiary Bacil Research and Development Pvt Ltd enters agreement with Efdee Pharma Pvt Ltd for R&D of pharmaceutical products • Scope covers development of pellets, granules, powders, tablets and capsules • Total estimated project cost at ₹35 Cr • Agreement dated November 4, 2026; director Chaitali Shah authorised to execute documents and complete formalities for the WOS

Bacil Pharma Ltd

Open attachment

← Back to feed